101 related articles for article (PubMed ID: 11774603)
1. Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor.
Nawrocki S; Łaciak M; Izycki D; Gryska K; Wysocki PJ; Grabarczyk P; Karczewska A; Kaczmarek A; Murawa P; Malicki J; Rose-John S; Mackiewicz A
Adv Exp Med Biol; 2001; 495():411-8. PubMed ID: 11774603
[No Abstract] [Full Text] [Related]
2. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
3. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials.
Nawrocki S; Murawa P; Malicki J; Kapcinska M; Gryska K; Izycki D; Kaczmarek A; Laciak M; Czapczyk A; Karczewska A; Rose-John S; Mackiewicz A
Immunol Lett; 2000 Sep; 74(1):81-6. PubMed ID: 10996632
[TBL] [Abstract][Full Text] [Related]
4. Cytokine gene transfection for autologous and allogeneic melanoma vaccines.
Todryk S; Birchall L; Erlich R; Halanek N; Orleans-Lindsay JK; Dalgleish A
Adv Exp Med Biol; 2001; 495():365-8. PubMed ID: 11774594
[No Abstract] [Full Text] [Related]
5. Immunogene therapy of human melanoma. Phase I/II clinical trial.
Mackiewicz A; Kapcińska M; Wiznerowicz M; Malicki J; Nawrocki S; Nowak J; Murawa P; Sibilska E; Kowalczyk D; Lange A; Hawley RC; Rose-John S
Adv Exp Med Biol; 1998; 451():557-60. PubMed ID: 10026927
[No Abstract] [Full Text] [Related]
6. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
7. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
9. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
[TBL] [Abstract][Full Text] [Related]
10. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
12. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage.
Hodi FS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):673-8. PubMed ID: 16467076
[No Abstract] [Full Text] [Related]
13. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Rosenberg SA
Immunol Today; 1997 Apr; 18(4):175-82. PubMed ID: 9136454
[No Abstract] [Full Text] [Related]
14. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
15. Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5 years study.
Gkalpakiotis S; Arenberger P; Kremen J; Arenbergerova M
Exp Dermatol; 2010 Nov; 19(11):994-9. PubMed ID: 20812969
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines and immunotherapies: emerging perspectives.
Henderson RA; Mossman S; Nairn N; Cheever MA
Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
18. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
Biochem Soc Trans; 1995 Aug; 23(3):681-6. PubMed ID: 8566443
[No Abstract] [Full Text] [Related]
19. Melanoma vaccination: state-of-the-art and experimental approaches.
Jonasch E
Expert Rev Anticancer Ther; 2001 Oct; 1(3):427-40. PubMed ID: 12113109
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.
Huang SK; Okamoto T; Morton DL; Hoon DS
J Invest Dermatol; 1998 Oct; 111(4):662-7. PubMed ID: 9764850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
